Is Zentalis Pharmaceuticals, Inc. (ZNTL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 26.6% / 30% | 249.7% / 30% | 3.4% / 30% | 32.28% / 5% | ✗ NOT HALAL |
| DJIM | 26.6% / 33% | 249.7% / 33% | 3.4% / 33% | 32.28% / 5% | ✗ NOT HALAL |
| MSCI | 9.2% / 33% | 86.2% / 33% | 1.2% / 33% | 32.28% / 5% | ✗ NOT HALAL |
| S&P | 26.6% / 33% | 249.7% / 33% | 3.4% / 33% | 32.28% / 5% | ✗ NOT HALAL |
| FTSE | 9.2% / 33% | 86.2% / 33% | 1.2% / 50% | 32.28% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -49.5% | |
| Return on Assets (ROA) | -25.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$171M |
| Free Cash Flow | -$171M |
| Total Debt | $40M |
| Debt-to-Equity | 16.5 |
| Current Ratio | 6.9 |
| Total Assets | $430M |
Price & Trading
| Last Close | $2.67 |
| 50-Day MA | $2.58 |
| 200-Day MA | $1.80 |
| Avg Volume | 1.3M |
|
52-Week Range
$1.01
| |
About Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Zentalis Pharmaceuticals, Inc. (ZNTL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Zentalis Pharmaceuticals, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Zentalis Pharmaceuticals, Inc.'s debt ratio?
Zentalis Pharmaceuticals, Inc.'s debt ratio is 26.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 9.2%.
What are Zentalis Pharmaceuticals, Inc.'s key financial metrics?
Zentalis Pharmaceuticals, Inc. has a market capitalization of $149M, and revenue of $67M. Return on equity stands at -49.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.